[2-(4-Methanesulfonyl-phenyl)-ethyl]-methyl-amine | 55664-71-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-(4-Methanesulfonyl-phenyl)-ethyl]-methyl-amine
• 英文别名: [2-(4-Methanesulfonylphenyl)ethyl](methyl)amine；N-methyl-2-(4-methylsulfonylphenyl)ethanamine
• CAS: 55664-71-6
• 化学式: C₁₀H₁₅NO₂S
• 分子量: 213.301
• InChiKey: ZBEQKZQMFKRETM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TETRACYCLIC ANTHRAQUINONE DERIVATIVES
  申请人：TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.

  公开号：US20170247403A1

  公开（公告）日：2017-08-31

  Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , W, n are defined as in the present application.
• PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS
  申请人：RESEARCH TRIANGLE INSTITUTE

  公开号：US20200030287A1

  公开（公告）日：2020-01-30

  Neuropeptide FF receptor modulators based on a proline scaffold are provided which offer NPFF receptor potencies in the nanomolar range and antagonistic selectivity for the NPFF1 receptor. Methods, compounds and compositions for modulating the function of neuropeptide FF receptors are provided for pharmacotherapies capable of influencing conditions or disorders affected by the neuropeptide FF receptors.
• [EN] PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] COMPOSES DE PYRAZOLO[3,4-B]PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTERASE
  申请人：GLAXO GROUP LTD

  公开号：WO2004024728A2

  公开（公告）日：2004-03-25

  The invention relates to a compound of formula (I) or a salt thereof: wherein:R1 is C1-4alkyl, C1-3fluoroalkyl, -CH2CH2OH or -CH2CH2CO2C1-2alkyl;R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;R3 is optionally substituted C3-8cycloalkyl or optionally substituted mono-unsaturated-C5-7cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n1 and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10; or R3 is a bicyclic group (dd) or (ee): ; and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.